Item 2.02 Results of Operations and Financial Condition.

On May 13, 2022, Zosano Pharma Corporation (the "Company") issued a press release titled "Zosano Pharma Reports First Quarter 2022 Financial Results." The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 10, 2022, Joseph "Jay" P. Hagan tendered his resignation as a director of the board of directors (the "Board") of the Company and as chairperson of the audit committee of the Board, effective immediately. Mr. Hagan's resignation is not based on any disagreement with the Company on any matter relating to the Company's operations, policies or practice.

Following Mr. Hagan's resignation, on May 10, 2022, pursuant to the authority contained in the Company's amended and restated certificate of incorporation, the Board approved decreasing the size of the Board to five members.

Item 9.01 Financial Statements and Exhibits.



(d)Exhibits.

  Exhibit                                             Description

   99.1                Press release dated May 13, 2022, titled "Zosano Pharma Reports First
                     Quarter 2022 Financial Results"

  104.1              Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses